News

Invitation to Nano2Clinic members to Contribution to Special Issue on “Selective Antitumor Therapy Based on Nanotechnology” in Pharmaceutics

Dr. Rosario M. Sánchez Martín, Guest Editor of a Special Issue of the journal Pharmaceutics entitled “Selective Antitumor Therapy Based on Nanotechnology”, will like to invite our Nano2Clinic members to contribute to this special issue. 

Pharmaceutics has received an updated Impact Factor of 6.321, as published in the 2020 Edition of the Journal Citation Reports® (Clarivate), the 5-Year Impact Factor is 6.734. It now ranks 28/275 (Q1) in  Pharmacology & Pharmacy.


Deadline for submission is * 15 September 2022 *.

 

Please access to the following link for further reading about this special issue:
https://www.mdpi.com/journal/pharmaceutics/special_issues/selective_antitumor

 

Rosario M. Sánchez Martín

Email :rosario.sanchez@genyo.es
 

Short Term Scientific Mission (STSM) Applications: Call #7 now open

Dear COSTers,

the 7th call for STSM Application is now open. All details can be found in the Call text which ca be downloaded from the dedicated page.

Please note that STSMs granted within the 7th call must be carried out from 20/05/2022 to 31/10/2022, and that all candidates are requested to submit their STSM applications no later than 10/05/2022.

Special Issue on “Dendrimers for Drug Delivery” in the Pharmaceutics Journal

 

Dear COSTers, 

 

As the guest editor of the Pharmaceutics Special Issue on “Dendrimers for Drug Delivery”, I would like to cordially invite you to contribute (either alone or with a colleague/post-doc, etc.) with a submission to this Issue. 

 

We would be happy to receive your excellent contributions to this special issue. Should your response be positive, we would appreciate receiving within the next month a short tentative abstract (100-150 words) describing the topic covered in your contribution. There is plenty of time for preparing your contribution, the deadline for submission being *20 September 2022*. You may send your manuscript now or up until the deadline. 

 

Please access to the following link for further reading about this special issue:

https://www.mdpi.com/journal/pharmaceutics/special_issues/dendrimers_delivery

 

We are pleased to announce that Pharmaceutics has received an updated Impact Factor of 6.321, as published in the 2020 Edition of the Journal Citation Reports® (Clarivate), the 5-Year Impact Factor is 6.734. It now ranks 28/275 (Q1) in the 'Pharmacology & Pharmacy' category. Besides, Pharmaceutics has received an increased CiteScore of 4.7 in the latest 2020 CiteScore™ values. 

 

Currently, an Article Processing Charges of 2400 CHF (Swiss Francs) applies to papers accepted after peer review. Besides, you could enjoy 15% discount as the invited paper. 

 

Benefits of publishing in Pharmaceutics: 1. Open access and high visibility: unlimited access, broad database coverage, various promotional activities and academic event presentations; 2. Rapid turn-around: 13.5 days from submission to first decision.

 

If you have any questions, you could contact the assistant editor Zora Zhou (zora.zhou@mdpi.com) directly.

We hope that you will agree to join us in this exciting and important special issue. We look forward to hearing from you.

Many thanks and warm personal regards,

Dr. Evgeny Apartsin
Guest Editor

#MyCa17140memories prize contest launched!

Dear COSTers,

the #MyCA17140memories prize contest has been launched. The idea is to gather as many as possible messages about our Action directed to the general public to be collected, published on our website on this dedicated page and on social media, and forwarded to the COST Head Quarters. The best initiatives will be awarded a prize as follows:

1st most original and best contribution - 300 Euros

2nd most original and best contribution . 200 Euros

3rd most original and best contribution . 100 Euros

All information, requirements, memory formats etc. are available on our website at the dedicated page: #myCa17140memories

Deadline: July 1, 2022

Webinar- PK/PD relationships of anticancer agents: Could nanoparticles change the game?

Dear COSTers,

As part of the Working Group #4 activities, it is our pleasure to invite you to attend the next webinar of our Action that will be held on Thursday 21 April at 15h CET.

The webinar: PK/PD relationships of anticancer agents: Could nanoparticles change the game? will be presented by Prof. Joseph Ciccolini, a KOL in pharmacokinetics, pharmacodynamics, and pharmacometrics in oncology.

We wait for you!

To access the meeting click here.

Pr Joseph Ciccolini, Pharm.D. Ph.D., is Full Professor of Pharmacokinetics at Aix Marseille University and Clinical Pharmacologist at La Timone University Hospital of Marseille, France. Pr Ciccolini is Group Leader at the SMARTc platform in Pharmacokinetics and Group Leader at the COMPO research unit (Cancer Research Center of Marseille,  Inserm U1068). Pr Ciccolini chairs the Digipharm Master program dedicated to Digital Tools in Pharmaceutical Sciences at Aix Marseille University, Marseille France.

Pr Ciccolini's expertise in clinics is mostly based on controlling the pharmacokinetics variability of anticancer agents, ranging from canonical cytotoxics,  oral targeted therapies to biologics such as immune-oncology drugs.    Pr Ciccolini has P.I.'ed or co-P.I.'ed several clinical trials investigating on the pharmacokinetics, pharmacodynamics and pharmacogenetics of several anticancer drugs. At the bench, Pr Ciccolini's work focuses on developing nanoparticles cargoing cytotoxics (i.e., liposomes, immunoliposomes) to target colorectal cancers and breast cancers, alone or combined with immune checkpoint inhibitors.  Pr Ciccolini has co-authored more than 150 international papers in both experimental and clinical pharmacokinetics, and owns several patents in the field. Joseph Ciccolini is the current Secretary of the PAMM-EORTC European group dedicated to promoting pharmacokinetics, pharmacodynamics and pharmacometrics in oncology. In a parallel life, Pr Ciccolini is also a bee-keeper and honey-maker in Corsica, France. 

European Cooperation in Science and Technology (COST) logo
Funded by the European Union